News
Welcome to AIHTA!
AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 50
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma
Newsletter
Project / High tech medicine, European collaboration
HTA Strategy for Lithuania
Project leaders: Claudia Wild
Project team: Claudia Wild, Tarquin Mittermayr
Duration: February 2015 - July 2015
Publication: HTA Decision Support Document No. 90a: https://eprints.aihta.at/1064/
Newsletter
Announcement
Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report
A Belgian KCE-Assessment analysed – as an update of the 2007 report – the evidence for hadron therapy (proton and carbon ions) in 15 paediatric indications. Since 2015 the Austrian MedAustron started operating and the first patients are treated, the LBI -HTA has been involved in the Belgian report as external expert. Now the LBI -HTA wrote – due to the regional relevance – a German summary of the Belgian report.
In the assessment 21 clinical studies (non-randomized, non-controlled and mostly retrospective) were found. All studies showed serious methodological flaws. The conclusion therefore is that to date clinical data on PBT in all paediatric cancers under study are lacking as well as critical information on long-term effectiveness and harms.
Prospective comparative clinical trials in the field are urgently needed.
Publication: Decision Support Document Nr. 88: https://eprints.aihta.at/1049
Contact: Claudia Wild
Announcement
Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases
The systematic review assessed the efficacy and safety of a treatment of chronic venous insufficiency (CVI) and haemorrhoidal diseases (HD) with capillary stabilising agents that are listed in the Austrian Code of Reimbursement.
A total of 56 studies were included for a data synthesis.
The majority of studies have shown that the symptoms and signs of CVI and HD can be reduced slightly with the agents (mostly when compared to placebo). Only minor side effects occurred.
However, the strength of the evidence of nearly all identified studies is low. Therefore, we cannot draw a final conclusion on the efficacy of capillary stabilising agents for the treatment of CVI and HD.
Publication: LBI-HTA Project report No. 79: https://eprints.aihta.at/1047
Contact: Stefan Fischer
Newsletter
Announcement
PET/PET-CT Evidence for need based planning (in oncology indications)
In nearly all Western countries, HTA-reports on Positron Emission Tomography/PET imaging have been written in the last two decades. 155 only in the last 10 years (!) Hardly any other medical technology has undergone so many evaluations. This large abundance is ultimately an expression of an unfading uncertainty about the value of PET imaging in patient care. The (Austrian) HTA report has the intention of supplying decision support for evidence- and needs-based PET device planning. Results from 35 HTAs and recommendations from 7 medical societies have been taken into consideration in the HTA report.
Publication: LBI-HTA Project report No. 77: https://eprints.aihta.at/1045
Contact: Claudia Wild
Event archive
Event
“Fraud, corruption and waste in healthcare: the EHFCN – Typology”
The event is organized in a cooperation between LBI-HTA/ Ludwig Boltzmann Institute for Health Technology Assessment and TI-AC/ Transparency International – Austrian Chapter.
Tuesday, March 3, 2015, 4:00 p.m. to 6:00 p.m.
Library of the Medical Society























